Add to ORKGThe malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine’s safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 1
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria...
Background The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Org...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Ken...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
Our aim was to evaluate the safety, reactogenicity, and immunogenicity of an investigational malaria...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and t...
Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunog...
A malaria vaccine could be an important addition to current control strategies. We report the safety...
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria...
in children exposed to seasonal falciparum malaria., or rabies vaccine. Three doses of vaccine were...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria...
Background The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Org...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Ken...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
Our aim was to evaluate the safety, reactogenicity, and immunogenicity of an investigational malaria...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and t...
Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunog...
A malaria vaccine could be an important addition to current control strategies. We report the safety...
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria...
in children exposed to seasonal falciparum malaria., or rabies vaccine. Three doses of vaccine were...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria...
Background The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Org...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...